Study of NRG-103 injection for recurrent high-grade glioma
Part of Cancer clinical trials.
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a high-grade glioma (WHO Grade 3 or 4) that has come back or kept growing after treatment.
- Standard treatments (like chemo, radiation, or immunotherapy) have either stopped working or caused serious side effects.
- You cannot have had gene therapy or virus-based cancer treatment before.
- You must be able to have an MRI scan (no metal implants like pacemakers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MT027, for people with high-grade glioma (a type of brain tumor) that has come back or continued to grow after standard treatment. The drug targets a protein called B7-H3 found on tumor cells. The goal is to see if it can help shrink tumors or slow the disease.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This study is testing a new way to target radiation for people with high-grade gliomas (aggressive brain tumors). The goal is to see if a more precise treatment plan can improve outcomes while keeping side effects low.
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
This trial tests an injection called NRG-103 given directly into the cavity where a recurrent brain tumor was removed. It is for people with glioblastoma that has come back and who have already had standard treatments.
Hear when a new HGG trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.